...
首页> 外文期刊>BioSystems >First report on exploring structural requirements of alpha and beta thymidine analogs for PfTMPK inhibitory activity using in silico studies
【24h】

First report on exploring structural requirements of alpha and beta thymidine analogs for PfTMPK inhibitory activity using in silico studies

机译:关于使用计算机模拟研究探索α和β胸苷类似物对PfTMPK抑制活性的结构要求的第一份报告

获取原文
获取原文并翻译 | 示例

摘要

With the emergence of multi-drug resistance of the currently available antimalarial drugs including the "magic bullet" artemisinin derivatives in the market, there is an urgent need for discovery and development of new potent antimalarial molecules. The present work deals with quantitative structure-activity relationship (QSAR) modeling, pharmacophore mapping and docking studies of a series of 35 thymidine analogs as inhibitors of Plasmodium falciparum thymidylate kinase (PfTMPK), an enzyme that catalyzes phosphorylation of thymidine monophosphate (TMP) to thymidine diphosphate (TDP). The models were validated both internally and externally and significant statistical results were obtained, indicating the robustness and reliability of the developed models. The docking study was performed using the LigandFit option of receptor-ligand interactions protocol section available in Discovery Studio 2.1 where lower RMSD values (0.6931. ?) between the co-crystallized ligand and re-docked ligand assured that the ligand was bound in the same binding pocket. The QSAR, pharmacophore mapping and docking studies provide an understanding of important structural requirements or essential molecular properties, or features of molecules, and important binding interactions, and provide an important guidance for the chemist to synthesis of new molecules with improved PfTMPK inhibitory activity profile. This work revealed the importance of -NH-fragment, electrophilicity of the molecules and the number of oxygen atom towards the PfTMPK inhibitory activity of the molecules. To the best of our knowledge, this work presents the first QSAR and pharmacophore report for thymidine analogs which may serve as an efficient tool for the design and synthesis of potent molecules as PfTMPK inhibitors to address the increasing threat of multi-drug resistance against P. falciparum.
机译:随着市场上当前可用的抗疟药包括“魔术子弹”青蒿素衍生物的多药耐药性的出现,迫切需要发现和开发新的有效抗疟分子。本工作涉及作为恶性疟原虫胸苷酸激酶(PfTMPK)抑制剂的一系列35种胸苷类似物的定量结构-活性关系(QSAR)建模,药效团作图和对接研究,该酶催化单磷酸胸苷(TMP)磷酸化为胸苷二磷酸酯(TDP)。对模型进行了内部和外部验证,并获得了重要的统计结果,表明所开发模型的鲁棒性和可靠性。对接研究是使用Discovery Studio 2.1中可用的受体-配体相互作用协议部分的LigandFit选项进行的,其中共结晶配体和重新对接的配体之间的RMSD值较低(0.6931。?),可确保该配体结合在同一配体中装订袋。 QSAR,药效团作图和对接研究提供了对重要结构要求或基本分子特性或分子特征以及重要结合相互作用的理解,并为化学家合成具有改进的PfTMPK抑制活性图的新分子提供了重要指导。这项工作揭示了-NH片段的重要性,分子的亲电性以及针对分子的PfTMPK抑制活性的氧原子数。据我们所知,这项工作提出了关于胸苷类似物的第一个QSAR和药效基团报告,可作为设计和合成有效分子的有效工具,作为PfTMPK抑制剂来解决对P的多重耐药性日益增加的威胁。恶性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号